About Clementia Pharmaceuticals (NASDAQ:CMTA)
Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models. It is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). Its programs focus on diseases involving tissue transformation via retinoic acid receptors (RARs). The Company also has an eye drop formulation of palovarotene that can potently increase tear production and decrease corneal damage.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-2.40234375
Forward P/E Ratio-1.57
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on Assets-211.59%
Clementia Pharmaceuticals (NASDAQ:CMTA) Frequently Asked Questions
What is Clementia Pharmaceuticals' stock symbol?
Clementia Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMTA."
When will Clementia Pharmaceuticals make its next earnings announcement?
Where is Clementia Pharmaceuticals' stock going? Where will Clementia Pharmaceuticals' stock price be in 2018?
4 brokers have issued 12 month target prices for Clementia Pharmaceuticals' shares. Their predictions range from $23.00 to $32.00. On average, they expect Clementia Pharmaceuticals' share price to reach $27.00 in the next year. View Analyst Ratings for Clementia Pharmaceuticals.
Who are some of Clementia Pharmaceuticals' key competitors?
Some companies that are related to Clementia Pharmaceuticals include Jounce Therapeutics (JNCE), Rhythm Pharmaceuticals (RYTM), Sorrento Therapeutics (SRNE), Karyopharm Therapeutics (KPTI), Inflarx (IFRX), Kura Oncology (KURA), Reata Pharmaceuticals (RETA), CymaBay Therapeutics (CBAY), Rocket Pharmaceuticals (RCKT), Akebia Therapeutics (AKBA), NuCana (NCNA), Five Prime Therapeutics (FPRX), Aclaris Therapeutics (ACRS), Keryx Biopharmaceuticals (KERX), G1 Therapeutics (GTHX), Insys Therapeutics (INSY), Rigel Pharmaceuticals (RIGL) and Dicerna Pharmaceuticals (DRNA).
Who are Clementia Pharmaceuticals' key executives?
Clementia Pharmaceuticals' management team includes the folowing people:
- David Bonita M.D., Chairman of the Board (Age 41)
- Clarissa Desjardins Ph.D., Chief Executive Officer, Founder, Director
- Michael Singer, Chief Financial Officer (Age 50)
- Eric Grinstead, Chief Commercial Officer
- Donna Grogan M.D., Chief Medical Officer
When did Clementia Pharmaceuticals IPO?
(CMTA) raised $101 million in an IPO on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and Leerink Partners acted as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.
When did Clementia Pharmaceuticals' lock-up period expire?
Clementia Pharmaceuticals' lock-up period expired on Monday, January 29th. Clementia Pharmaceuticals had issued 8,000,000 shares in its initial public offering on August 2nd. The total size of the offering was $120,000,000 based on an initial share price of $15.00. Since the end of Clementia Pharmaceuticals' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
Who owns Clementia Pharmaceuticals stock?
Clementia Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include
ORBIMED ADVISORS LLC
ORBIMED ADVISORS LLC
(32.87%), Driehaus Capital Management LLC (2.82%), Sectoral Asset Management Inc (0.25%), Victory Capital Management Inc. (0.11%) and Alps Advisors Inc. (0.11%). View Institutional Ownership Trends for Clementia Pharmaceuticals.
Who sold Clementia Pharmaceuticals stock? Who is selling Clementia Pharmaceuticals stock?
Who bought Clementia Pharmaceuticals stock? Who is buying Clementia Pharmaceuticals stock?
Clementia Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Driehaus Capital Management LLC, Alps Advisors Inc., J. Goldman & Co LP and Victory Capital Management Inc.. View Insider Buying and Selling for Clementia Pharmaceuticals.
How do I buy Clementia Pharmaceuticals stock?
Shares of Clementia Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clementia Pharmaceuticals' stock price today?
One share of Clementia Pharmaceuticals stock can currently be purchased for approximately $12.30.
How big of a company is Clementia Pharmaceuticals?
Clementia Pharmaceuticals has a market capitalization of $365.02 million. The company earns $-57,510,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Clementia Pharmaceuticals employs 24 workers across the globe.
How can I contact Clementia Pharmaceuticals?
Clementia Pharmaceuticals' mailing address is 4150 Sainte-Catherine St W Suite 550, WESTMOUNT, QC H3Z 2Y5, Canada. The company can be reached via phone at +1-514-9403600 or via email at in[email protected]
MarketBeat Community Rating for Clementia Pharmaceuticals (CMTA)MarketBeat's community ratings are surveys of what our community members think about Clementia Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Clementia Pharmaceuticals (NASDAQ:CMTA) Earnings History and Estimates Chart
Clementia Pharmaceuticals (NASDAQ CMTA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/26/2018|| || || || || || || || |
Clementia Pharmaceuticals (NASDAQ:CMTA) Earnings Estimates
2018 EPS Consensus Estimate: ($1.58)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Clementia Pharmaceuticals (NASDAQ:CMTA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Clementia Pharmaceuticals (NASDAQ CMTA)
No insider trades for this company have been tracked by MarketBeat.com
Clementia Pharmaceuticals (NASDAQ CMTA) News Headlines
Clementia Pharmaceuticals (NASDAQ:CMTA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Clementia Pharmaceuticals (NASDAQ:CMTA) Income Statement, Balance Sheet and Cash Flow Statement
Clementia Pharmaceuticals (NASDAQ CMTA) Stock Chart for Wednesday, February, 21, 2018